A pioneering medical trial has discovered that providing pluripotent cells to fetuses diagnosed with spina bifida during corrective surgery can be a "significant breakthrough" in treating birth defects.
Study Parameters and Security
The US-based trial examined six unborn babies with myelomeningocele. Surgeons applied regenerative cells sourced from the maternal placenta to the surface of the baby's spinal cord while the defect was being closed.
Importantly, the cell therapy was found to be safe. Researchers confirmed that the treatment did not lead to neoplasms, hinder surgical recovery, or block the correction of co-occurring hindbrain herniation.
Promising Outcomes
Magnetic resonance imaging performed on the newborns indicated a complete reversal of brainstem displacement in every participant. This favorable anatomical change is strongly associated with improved motor skills and quality of life.
"In the event it allows additional babies capable of walking who previously could not, it may emerge as the new treatment paradigm," said the lead researcher. "The outcomes appear extremely promising and create a pathway toward a variety of prospective novel therapies."
Long-Term Prospects and Optimism
Independent medical specialists proposed that additional validation of these noted improvements could herald a "different age" in in-utero treatment. The potential to improve neural deficits seen in utero is viewed as a transformative goal.
Especially significant would be better management of bladder and bowel function, which are typical difficulties for people affected by this condition.
The Path Forward
Despite this being a first-in-human effort was small in scale, its confirmed tolerability and hopeful trends create a solid basis for larger, more comprehensive studies. The addition of cellular treatment with current in-utero repair procedures holds considerable promise for transforming outcomes for future generations with myelomeningocele.